Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283413 · ClinicalTrials.gov registry record · NA
Symbiot III: A Prospective Randomized Trial Evaluating the Symbiot Covered Stent System in Saphenous Vein Grafts
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 514
- Enrollment target
NCT00283413 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 514 participants.
The verdict
NCT00283413, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 514 participants
- Enrollment target
Study Summary
The objective of the Symbiot III Clinical Trial was to evaluate the safety and effectiveness of the Symbiot Covered Stent System in the treatment of symptomatic ischemic saphenous vein bypass graft disease.
Interventions
- DEVICE Bare metal stent
- DEVICE Covered Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2002-03 |
| Est. Completion | 2009-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283413
The ClinicalTrials.gov registry entry for NCT00283413 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bare metal stent is the first listed.
NCT00283413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283413 about?
NCT00283413 is a clinical study titled "Symbiot III: A Prospective Randomized Trial Evaluating the Symbiot Covered Stent System in Saphenous Vein Grafts". The objective of the Symbiot III Clinical Trial was to evaluate the safety and effectiveness of the Symbiot Covered Stent System in the treatment of symptomatic ischemic saphenous vein bypass graft disease.
What is the current status of trial NCT00283413?
This trial is currently completed. It is a NA study. The enrollment target is 514 participants. The study started on 2002-03. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00283413?
The interventions under investigation include: Bare metal stent (DEVICE), Covered Stent System (DEVICE).
Who is sponsoring clinical trial NCT00283413?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.